Open AccessExpressions of SH 3 BP 5, LMO 3, and SNAP 25 in diffuse large B‐cell lymphoma cells and their association with clinical features
Author(s) -
Kobayashi Kyoko,
Yamaguchi Motoko,
Miyazaki Kana,
Imai Hiroshi,
Yokoe Kaori,
Ono Ryoichi,
Nosaka Tetsuya,
Katayama Naoyuki
Publication year - 2016
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.753
Subject(s) - snap , lymphoma , biology , computer science , immunology , computer graphics (images)
Diffuse large B‐cell lymphoma ( DLBCL ) is clinicopathologically and genetically heterogeneous with variable clinical outcomes. We previously identified signature genes overexpressed in CD 5‐positive ( CD 5 + ) DLBCL , which is a poor prognostic subgroup of DLBCL . To elucidate the clinical significance of the protein expression of the signature genes overexpressed in CD 5 + DLBCL with regard to all DLBCL , not otherwise specified ( NOS ), 10 genes ( SH 3 BP 5 , LMO 3 , SNAP 25 , SYT 5 , SV 2C , CABP 1 , FGF 1 , FGFR 2 , NEUROD 1 , and SYN 2 ) were selected and examined immunohistochemically with samples from 28 patients with DLBCL , NOS . Only three protein expressions, SH 3 BP 5, LMO 3, and SNAP 25, were detected in DLBCL cells and then analyzed further with samples from 187 patients with DLBCL , NOS . The SH 3 BP 5, LMO 3, and SNAP 25 proteins were expressed in 60% (103/173), 34% (59/175), and 46% (77/168) of DLBCL patients, respectively. These protein expressions were associated with CD 5 expression, and only SH 3 BP 5 was frequently expressed in activated B‐cell‐like DLBCL ( P = 0.046). Compared to the SH 3 BP 5‐negative group, the SH 3 BP 5 + group was correlated with elderly onset (>60 years, P = 0.0096) and advanced‐stage disease (stage III / IV , P = 0.037). The LMO 3 + group showed a worse performance status (>1, P = 0.0004). The SH 3 BP 5 + group and the LMO 3 + group had significantly worse overall survival than the negative groups ( P = 0.030, 0.034; respectively) for the entire group. In a subgroup analysis of patients treated with rituximab‐containing chemotherapy, there was no significant difference between groups. To the best of our knowledge, this is the first report showing the protein expressions of SH 3 BP 5, LMO 3, and SNAP 25 in DLBCL cells and their clinical significance in patients with DLBCL . The SH 3 BP 5 and LMO 3 protein expressions are associated with the baseline clinical characteristics of DLBCL .